# Real World Study of Oxycodone/Naloxone Sustained-Release Tablets (Mimeixin) for Patients With Severe Cancer Pain

> **NCT06897917** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Henan Cancer Hospital** · enrollment: 203 (estimated)

## Conditions studied

- Opioid-Induced Constipation
- Pain Cancer

## Interventions

- **DRUG:** Oxycodone Hydrochloride and Naloxone Hydrochloride Sustained-release Tablets

## Key facts

- **NCT ID:** NCT06897917
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-04
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 203 (ESTIMATED)
- **Last updated:** 2025-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06897917

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06897917, "Real World Study of Oxycodone/Naloxone Sustained-Release Tablets (Mimeixin) for Patients With Severe Cancer Pain". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06897917. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*